Navigation Links
Wyeth Research Head Robert R. Ruffolo, Jr., Ph.D., Announces Retirement

- Mikael Dohlsten, M.D., Ph.D., To Succeed As President, Wyeth Research -

MADISON, N.J., April 30 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced that Robert R. Ruffolo, Jr., Ph.D., 58, will retire as President, Wyeth Research and Senior Vice President, Wyeth, later this year. He will be succeeded by Mikael Dohlsten, M.D., Ph.D.

Dr. Ruffolo joined Wyeth in November 2000 and has been responsible for all pharmaceutical research and development (R&D) for the Company, including discovery, drug safety and metabolism, chemical and pharmaceutical development, clinical R&D and research operations.

"Bob Ruffolo has been the driving force of our R&D progress, establishing Wyeth as one of the research leaders in the pharmaceutical industry," says Bernard Poussot, Wyeth's President and Chief Executive Officer. "His legacy will be our pipeline, recognized as one of the industry's most innovative. Bob has helped position our company for future growth through robust research and development programs in oncology, women's health, vaccines, inflammation, cardiovascular and metabolic diseases and neuroscience -- led by our multi-platform effort in Alzheimer's."

Throughout his 31-year career in the pharmaceutical industry, Dr. Ruffolo's work has been recognized with a number of prestigious awards. In March, he was recognized by the Pharmaceutical Research and Manufacturers of America (PhRMA) with the 2008 Discoverer's Award for his efforts in the discovery and development of Coreg(R) while at GlaxoSmithKline. The Wyeth Research and Development Executive Team (RADEX), formed and chaired by Dr. Ruffolo, won the 2006 Scrip Award for Management Team of the Year. In 2005, he won the George B. Koelle Award for Scientific Excellence. In 2004, he was named Chief Scientific Officer of the Year by IBC Conferences.

Dr. Dohlsten, 49, previously was Executive Vice President within Pharmaceutical Research & Development/Medicine at Boehringer Ingelheim. He was responsible for leading the company's worldwide pharmaceutical research in the U.S., Canada, Germany, Italy, Austria and Japan - with major programs in seven therapeutic areas including respiratory, inflammation/immunology, oncology, virology, cardiovascular, metabolism and CNS. In addition, he was a member of the corporate management team responsible for reviewing all worldwide development projects and licensing opportunities. Prior to joining Boehringer Ingelheim, Dr. Dohlsten spent more than 15 years in various leadership roles in pharmaceutical research including positions with AstraZeneca and Pharmacia & Upjohn.

Dr. Dohlsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He also studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund.

"We look forward to Dr. Dohlsten's leadership as we work together to continue our success at Wyeth Research," says Bernard Poussot. "His experience with industry in a broad range of therapeutic areas, and his vision going forward, match well with our scientific objectives. We know Mikael's global experience and perspective will be an inspiration to Wyeth's outstanding research teams."

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Chairman Robert Essner Announces June 27 Retirement
2. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
3. Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
4. Wyeth Sets Webcast And Conference Call For 2008 First Quarter Earnings
5. Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts
6. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
7. Wyeth Announces Executive Change in Finance Organization
8. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
9. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
10. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
11. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
Post Your Comments:
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):